Search results for "BODIES"

showing 10 items of 2217 documents

A swallowed toothbrush

2001

A 27-year-old woman came to the emergency department in April, 1999, after swallowing a toothbrush while cleaning her teeth 1 hour previously. She attributed the accident to clumsiness which made her slip on the wet bathroom floor, thereby forcing the toothbrush deep into her throat She reported no other illnesses. She had no pain, dysphagia, or dyspnoea. On examination she had a normal weight (body mass index of 22 kg/m). Her oropharnyx had no signs of injury and the rest of the physical examination was normal. A chest radiograph showed a toothbrush projecting towards the distal oesophagus with the head pointing to the oropharynx (figure), a finding which was not compatible with the report…

AdultToothbrushingmedicine.medical_specialtyPhysical examinationlaw.inventionEsophagusSwallowinglawThroatotorhinolaryngologic diseasesmedicineHumansBulimiamedicine.diagnostic_testbusiness.industryGeneral MedicineForeign Bodiesmedicine.diseaseDysphagiaEndoscopySurgeryRadiographymedicine.anatomical_structureFemalemedicine.symptomToothbrushForeign bodybusinessChest radiographThe Lancet
researchProduct

Hepatitis B vaccination of relatives of hepatitis B virus DNA positive carriers: an experience with plasma-derived vaccine.

1989

We assessed in a western population the efficacy of a plasma-derived hepatitis B vaccine in relatives of highly infectious hepatitis B virus (HBV) carriers. A consecutive group of 103 HbsAg, anti-HBs and anti-HBc negative household relatives of 45 HBV-DNA positive chronic carriers received a 5 micrograms dose of plasma-derived vaccine at 0, 1, 2 and 12 months. Protective levels of immunity developed in 101 subjects (97.8%) 3 months after boosting. Low responders to the vaccine were mostly found among parents and spouses of carriers, whilst offspring and siblings were usually high responders. The main discriminant in predicting a good response was age below 12 years. Hyporesponsiveness did n…

AdultViral Hepatitis VaccinesHBsAgHepatitis B vaccineEpidemiologyPopulationmedicine.disease_causeImmune systemImmunityRisk FactorsMedicineHumansHepatitis B VaccinesHepatitis B AntibodieseducationHepatitis B viruseducation.field_of_studyHepatitis B Surface Antigensbusiness.industryInfant Newbornvirus diseasesInfantHepatitis Bmedicine.diseaseHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesVaccinationImmunologyCarrier StatebusinessDNA ProbesEuropean journal of epidemiology
researchProduct

The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion.

2007

The role of thrombophilia and thyroid autoimmunity in unexplained infertility (UI), implantation failure (IF) and recurrent spontaneous abortion (RSA) is controversial and poorly understood.From March, 2004 to January, 2007, 119 women were prospectively included: 32 oocyte donors, 31 patients with UI, 26 with IF and 30 with RSA. The IF and RSA groups presented normal preimplantation genetic screening. Protein C, protein S, antithrombin III, lupus anticoagulant, activated protein C resistance (APCR), immunoglobulin M and G anticardiolipin antibodies, homocystine, Factor V Leiden, prothrombin G20210A mutation, methylentetrahydrofolate reductase C677T mutation, thyroid-stimulating hormone (TSH…

Adultendocrine systemmedicine.medical_specialtyAbortion Habitualmedicine.medical_treatmentThyroid GlandAutoimmunityThrombophiliaGastroenterologyIodide PeroxidaseThyroglobulinAntiphospholipid syndromeInternal medicinemedicineFactor V LeidenPrevalenceHumansThrombophiliaEmbryo ImplantationProspective StudiesUnexplained infertilityActivated Protein C ResistanceAutoantibodiesLupus anticoagulantbusiness.industryRehabilitationThyroidObstetrics and Gynecologymedicine.diseaseEndocrinologymedicine.anatomical_structureReproductive MedicineLupus Coagulation InhibitorThyroglobulinFemaleActivated protein C resistancebusinessInfertility FemaleHuman reproduction (Oxford, England)
researchProduct

Subclinical hypothyroidism resulting from autoimmune thyroiditis in female patients with endogenous depression.

1994

Thyroid function and presence of thyroid autoantibodies were assessed in a group of 75 consecutive female patients with mood disturbances and in a group of 38 healthy women of similar age recruited as controls. Nine patients suffered from major (endogenous) depression and 66 from minor (neurotic) depression. The individual patients had normal values of circulating thyroid hormones. Nevertheless, endogenously depressed patients had total serum triiodothyronine (M±SE=1.49±0.09 nmol/l) and both total (83.9±4.3 nmol/l) and free serum thyroxine (13.9±1.1 pmol/l) lower than in the group of minor depressed and in the group of controls (p<0.01, in both comparison). The median value of serum thyrotr…

Adultendocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentThyrotropinThyroid function testsThyroglobulinThyroiditisAutoimmune thyroiditisEndocrinologyHypothyroidismThyroid peroxidaseInternal medicinemedicineHumansAgedAutoantibodiesDepressive DisorderTriiodothyroninebiologymedicine.diagnostic_testbusiness.industryThyroiditis AutoimmuneMiddle Agedmedicine.diseaseAnti-thyroid autoantibodiesEndocrinologybiology.proteinThyroglobulinFemaleThyroid functionbusinessJournal of endocrinological investigation
researchProduct

Possible link between Hashimoto's thyroiditis and oral lichen planus: a novel association found

2013

Objectives: Hashimoto's thyroiditis as well as lichen planus has been associated to a number of disorders, generally of auto-immune origin. A novel possible association between oral lichen planus (OLP) and Hashimoto's thyroiditis (HT) is here proposed on the basis of a cross-sectional survey. Materials and methods: One hundred and five unrelated OLP patients were considered. Diagnosis of HT was based on positive serum anti-TPO, anti-Tg, TSH levels and the typical ultrasound pattern of the thyroid gland. Results: In the present survey, the prevalence of HT in the OLP group was 14. 3 % whereas the prevalence of HT-related hypothyroidism in the general population was reported to be equal to 1 …

Adultendocrine systemmedicine.medical_specialtyendocrine system diseasesPopulationThyrotropinAutoimmunityHashimoto Diseasemedicine.disease_causeAutoantigensIodide PeroxidaseGastroenterologyAsymptomaticThyroiditisAutoimmunityHashimoto's thyroiditistomatognathic systemSettore MED/28 - Malattie OdontostomatologicheIron-Binding ProteinsInternal medicinePrevalencemedicineHumansThyroid NoduleOral mucosaeducationGeneral DentistryAutoantibodieseducation.field_of_studybusiness.industryThyroidMiddle AgedCirculating thyroid antibodiesmedicine.diseaseAnti-thyroid autoantibodiesThyroxinestomatognathic diseasesCross-Sectional Studiesmedicine.anatomical_structureItalyOral lichen planuHashimoto's thyroiditis; Oral lichen planus; Autoimmunity; Circulating thyroid antibodiesTriiodothyronineFemaleOral lichen planusmedicine.symptombusinessLichen Planus OralClinical Oral Investigations
researchProduct

Definition of discrete signals involved in human T-cell activation

1986

Abstract Mitogenic activities of monoclonal antibodies directed at denned receptor structures expressed on the surface of mature human T lymphocytes were employed to study, in detail, signals involved in primary T-cell activation. Based on differential requirements for stimulation, two discrete pathways of human T-cell activation can be defined: the antigen-induced mode of activation initiated through the Ti-T3 antigen-receptor complex and an alternative pathway which can be triggered by monoclonal antibodies directed at the T11 glycoprotein. Perhaps more importantly, the approach taken here allows the definition of stable intermediate cellular stages within the activation cascade and, thus…

Adultmedicine.drug_classT-LymphocytesT cellImmunologyReceptors Antigen T-CellAntigen-Presenting CellsStimulationBiologyLymphocyte ActivationMonoclonal antibodyMonocytesmedicineHumansReceptorMolecular Biologychemistry.chemical_classificationAntibodies MonoclonalCell biologySignallingmedicine.anatomical_structurechemistryAlternative complement pathwayInterleukin-2GlycoproteinInterleukin-1Molecular Immunology
researchProduct

Antiphospholipid syndrome in obstetrics.

2003

Antiphospholipid syndrome (APLS) in pregnancy is characterized by the presence of autoantibodies in association with recurrent fetal loss and severe complications such as preeclampsia, fetal growth retardation, or placental insufficiency. The most clinically important serologic markers are lupus anticoagulant, anticardiolipin antibodies, and recently anti-beta-2-glycoprotein 1 antibodies. At present, standardization does not exist and a definitive association between specific clinical manifestation and antibody level is not yet known. Experimental data gave evidence that passive transfer of antiphospholipid antibodies result in clinical manifestation of APLS, that is, fetal loss and thromb…

Adultmedicine.medical_specialtyAbortion HabitualPlacental insufficiency030204 cardiovascular system & hematologyGastroenterologyPreeclampsia03 medical and health sciences0302 clinical medicinePre-Eclampsiaimmune system diseasesAntiphospholipid syndromePregnancyInternal medicinemedicinePrevalenceHumansThrombophiliaAnnexin A5030203 arthritis & rheumatologyLupus anticoagulantAspirinPregnancyFetal Growth RetardationAspirinbusiness.industryHeparinStandard treatmentInfant NewbornAnticoagulantsImmunoglobulins IntravenousHematologyGeneral MedicineHeparinmedicine.diseaseAntiphospholipid SyndromePlacental InsufficiencyThrombocytopeniaAbortion SpontaneousPregnancy ComplicationsAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyPrednisoneFemalebusinessImmunity Maternally-AcquiredImmunosuppressive Agentsmedicine.drugClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 y…

2009

This observer-blind study compared the prophylactic human papillomavirus (HPV) vaccines, Cervarix (GlaxoSmithKline) and Gardasil (Merck), by assessing immunogenicity and safety through one month after completion of the three-dose vaccination course. Women (n = 1106) were stratified by age (18-26, 27-35, 36-45 years) and randomized (1:1) to receive Cervarix (Months 0, 1, 6) or Gardasil (Months 0, 2, 6). At Month 7 after first vaccination, all women in the according-to-protocol cohort who were seronegative/DNA negative before vaccination for the HPV type analyzed had seroconverted for HPV-16 and HPV-18 serum neutralizing antibodies, as measured by pseudovirion-based neutralization assay (PBNA…

Adultmedicine.medical_specialtyAdolescentImmunologyAntibodies ViralCancer VaccinesSerologyYoung AdultHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Neutralization TestsInternal medicinemedicineHumansPapillomavirus VaccinesGeneral Pharmacology Toxicology and PharmaceuticsNeutralizing antibodyPapillomaviridaeCervical cancerbiologybusiness.industryImmunogenicityGardasilPapillomavirus InfectionsMiddle Agedmedicine.diseaseAntibodies NeutralizingVaccinationImmunologyCohortbiology.proteinFemaleCervarixbusinessmedicine.drugHuman Vaccines
researchProduct

Rituximab in refractory pemphigus vulgaris

2008

Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and a…

Adultmedicine.medical_specialtyAntigens CD19B-Lymphocyte SubsetsDrug ResistanceDermatologyDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRituximab pemphigus vulgarisimmune system diseasesHumansImmunologic FactorsMedicineInfusions IntravenousCD20integumentary systembiologybusiness.industryRemission InductionPemphigus vulgarisAntibodies MonoclonalGeneral MedicineAntigens CD20medicine.diseaseDermatologyRegimenPemphigusMonoclonalImmunologybiology.proteinPrednisoneDrug Therapy CombinationFemaleRituximabRituximabbusinessImmunosuppressive AgentsPemphigusmedicine.drugDermatologic Therapy
researchProduct

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovaria…

2013

Summary Background In the Gynecologic Cancer Intergroup International Collaboration on Ovarian Neoplasms 7 (ICON7) trial, bevacizumab improved progression-free survival in patients with ovarian cancer when used in combination with first-line chemotherapy and as a single-drug continuation treatment for 18 cycles. In a preliminary analysis of a high-risk subset of patients, there was also an improvement in overall survival. This study aims to describe the health-related quality-of-life (QoL) outcomes from ICON7. Methods ICON7 is a randomised, multicentre, open-label phase 3 trial. Between Dec 18, 2006, and Feb 16, 2009, after a surgical procedure aiming to debulk the disease, women with Inter…

Adultmedicine.medical_specialtyBevacizumabDrug-Related Side Effects and Adverse ReactionsAntibodies Monoclonal HumanizedDisease-Free Survivallaw.inventionchemistry.chemical_compoundRandomized controlled trialQuality of lifelawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedNeoplasm StagingOvarian NeoplasmsIntention-to-treat analysisbusiness.industryStandard treatmentArticlesMiddle Agedmedicine.diseaseCarboplatinSurgeryBevacizumabClinical trialTreatment OutcomeOncologychemistryQuality of LifeFemaleOvarian cancerbusinessmedicine.drugThe Lancet Oncology
researchProduct